State Street Corp Nuvalent, Inc. Transaction History

State Street Corp

$2.21 Trillion
Q1 2024

A detailed history of State Street Corp transactions in Nuvalent, Inc. stock. As of the latest transaction made, State Street Corp holds 1,514,106 shares of NUVL stock, worth $115 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,514,106

Previous 1,701,234 11.0%

Holding current value

$115 Million

Previous $125 Million 9.19%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$72.35 - $88.99 $13.5 Million - $16.7 Million	-187,128 Reduced 11.0%	1,514,106 $114 Million
Q4 2023 Feb 14, 2024	BUY	$42.42 - $80.28 $18.7 Million - $35.4 Million	440,768 Added 34.97%	1,701,234 $125 Million
Q3 2023 Nov 14, 2023	BUY	$39.12 - $49.85 $3.62 Million - $4.61 Million	92,477 Added 7.92%	1,260,466 $57.9 Million
Q2 2023 Aug 14, 2023	BUY	$23.58 - $44.68 $2.94 Million - $5.58 Million	124,786 Added 11.96%	1,167,989 $49.3 Million
Q1 2023 May 15, 2023	BUY	$25.42 - $33.52 $5.34 Million - $7.04 Million	210,155 Added 25.23%	1,043,203 $27.2 Million

Q4 2022 Feb 14, 2023	BUY	$18.46 - $36.37 $9.94 Million - $19.6 Million	538,416 Added 182.74%	833,048 $24.8 Million
Q3 2022 Nov 15, 2022	BUY	$13.55 - $19.92 $139,199 - $204,638	10,273 Added 3.61%	294,632 $5.73 Million
Q2 2022 Aug 15, 2022	BUY	$7.4 - $15.07 $428,608 - $872,854	57,920 Added 25.58%	284,359 $3.86 Million
Q1 2022 May 16, 2022	BUY	$11.65 - $19.57 $675,536 - $1.13 Million	57,986 Added 34.42%	226,439 $3.15 Million
Q4 2021 Feb 14, 2022	BUY	$18.01 - $30.1 $532,051 - $889,214	29,542 Added 21.27%	168,453 $3.21 Million
Q3 2021 Nov 15, 2021	BUY	$18.25 - $38.35 $2.54 Million - $5.33 Million	138,911 New	138,911 $3.13 Million

Others Institutions Holding NUVL

# of Institutions

184

Shares Held

54.4M

Call Options Held

838K

Put Options Held

116K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.26B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Nuvalent, Inc. Transaction History